Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340651 · ClinicalTrials.gov registry record · Phase 2
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
A Phase 2 study of Myelofibrosis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 3
- Study locations
NCT01340651: Completed Phase 2 study of Myelofibrosis, sponsored by Incyte Corporation.
NCT01340651 is a Phase 2 study of Myelofibrosis that has completed, run by Incyte Corporation. The registered enrollment target is 41 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01340651, a Phase 2 study of Myelofibrosis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF).
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (3)
Arizona
- - Scottsdale
Florida
- - Winter Park
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01340651 record still lists
NCT01340651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT01340651 reports a single indexed study location in Arizona, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT01340651 about?
NCT01340651 is a clinical study titled "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients". The purpose of this study is to determine the safety and tolerability of ruxolitinib (INCB018424) sustained release (SR) formulation in participants with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF).
What is the current status of trial NCT01340651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-03. Estimated completion is 2012-07.
What conditions does trial NCT01340651 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT01340651?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01340651?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01340651 being conducted?
This trial has 3 study locations across Arizona, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01340651's enrollment target sits among peer trials
41 32nd of 61 higher than 30 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia